Invesco Ltd. filed an amended Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 1,852,539 shares of Charles River Laboratories International Inc as of September 30, 2026.

Key Highlights

  • Beneficial ownership: Invesco Ltd. reported aggregate beneficial ownership of 1,852,539 shares of Charles River Laboratories International Inc common stock.
  • Percent of class: The disclosed stake represents 3.9% of the outstanding class of common stock.
  • Sole voting power: Invesco Ltd. reported sole voting power over 1,845,388 shares, with zero shared voting power.
  • Sole dispositive power: Invesco Ltd. reported sole dispositive power over all 1,852,539 shares, with zero shared dispositive power.
  • Capacity disclosed: The filing states that Invesco Ltd. acts "in its capacity as a parent holding company to its investment advisers" with respect to these shares.
  • Subsidiaries identified: Three subsidiaries were listed as having acquired the securities: Invesco Advisers, Inc., Invesco Asset Management Limited, and Invesco Capital Management LLC.

Invesco Ltd. Discloses September 30, 2026 Holdings in Charles River Laboratories

Invesco Ltd., organized in Bermuda and headquartered at 1331 Spring Street NW, Suite 2500, Atlanta, GA 30309, filed Amendment No. 1 to its Schedule 13G on November 9, 2026, covering common stock of Charles River Laboratories International Inc (CUSIP 159864107), whose principal executive offices are located at 251 Ballardvale Street, Wilmington, MA 01887. The event triggering the filing occurred on September 30, 2026, according to the document.

According to the filing, Invesco Ltd. may be deemed to beneficially own 1,852,539 shares "which are held of record by clients of Invesco Ltd." The filing further states that "no one person has greater than 5% economic ownership in the securities listed above" and that the relevant clients hold the right to receive dividends and proceeds from any sale. Invesco Ltd. is classified in the filing as a parent holding company (HC) and investment adviser (IA).

The filing was signed by Robert R. Leveille, identified as Global Head of Compliance, on November 9, 2026. The certification included in the filing states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Invesco Ltd. disclosed amended Schedule 13G beneficial ownership of 1,852,539 shares, equal to 3.9% of Charles River Laboratories International Inc common stock, as of September 30, 2026, held through client accounts managed by its investment adviser subsidiaries.